The prevalence of penile HPV genotypes stratified by age group (16–20, 21–25, 26–30, or 31–35 years) are shown in Table 2 and illustrated in Figure 1. The combined prevalence of 4vHPV-targeted genotypes was low, at 2.7% and 3.7%, respectively, among men in the 16–20- and 21–25-year age groups, increasing significantly to 16.7% and 9.8% among those aged 25–29 or 30–35 years (Ptrend = .001). The prevalence of low-risk HPV genotypes 6 and 11 was 1.1% and 1.5% among men aged 16–20 or 21–25 years, increasing significantly to 9.3% and 6.1% among those aged 26–30 or 31–35 years, respectively (Ptrend = .003). The prevalence of high-risk HPV genotypes 16 and 18 was 1.6% and 2.2% among men aged 16–20 and 21–25 years, increasing significantly to 9.3% and 4.9% among those aged 26–30 and 31–35 years, respectively (Ptrend = .02). By contrast, the prevalence of high-risk HPV genotypes other than HPV-16/18 did not change with increasing age group (Ptrend = .77). There was no significant trend across age groups in the prevalence of any HPV genotype (Ptrend = .11) or in the prevalence of additional HPV genotypes that a 9vHPV vaccine would provide protection against (Ptrend= .50).
Table 2.
Prevalence of Penile HPV Genotypes by Age Group Among 511 Register-Confirmed Unvaccinated Australian Heterosexual Male Subjects
| HPV Genotype | Age 16–20 y (n = 185) | Age 21–25 y (n = 136) | Age 26–30 y (n = 108) | Age 31–35 y (n = 82) | Ptrend | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | ||
| Any | 39 | 21.1 (15.0–28.8) | 42 | 30.1 (22.3–41.7) | 40 | 37.0 (26.5–50.4) | 22 | 26.8 (16.8–40.6) | .11 |
| Vaccine targeted (6, 11, 16, or 18) | 5 | 2.7 (.9–6.3) | 5 | 3.7 (1.2–8.6) | 18 | 16.7 (9.9–26.3) | 8 | 9.8 (4.2–19.2) | .001 |
| Any high risk | 30 | 16.2 (10.9–23.1) | 26 | 19.1 (12.5–28.0) | 28 | 25.9 (17.2–37.5) | 15 | 18.3 (10.2–30.2) | .30 |
| High risk, other than 16 and 18 | 28 | 15.1 (10.1–21.9) | 26 | 19.1 (12.5–28.0) | 22 | 20.4 (12.8–30.8) | 12 | 14.6 (7.6–25.6) | .77 |
| 6 or 11 | 2 | 1.1 (.1–3.9) | 2 | 1.5 (.2–5.3) | 10 | 9.3 (4.4–17.0) | 5 | 6.1 (2.0–14.2) | .003 |
| 16 or 18 | 3 | 1.6 (.3–4.7) | 3 | 2.2 (.5–6.4) | 10 | 9.3 (4.4–17.0) | 4 | 4.9 (1.3–12.5) | .02 |
| 31, 33, 45, 52, or 58 | 12 | 6.5 (3.4–11.3) | 16 | 11.8 (6.7–19.1) | 8 | 7.4 (3.2–14.6) | 3 | 3.7 (.8–10.7) | .50 |
| HPV Genotype | Age 16–20 y (n = 185) | Age 21–25 y (n = 136) | Age 26–30 y (n = 108) | Age 31–35 y (n = 82) | Ptrend | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | ||
| Any | 39 | 21.1 (15.0–28.8) | 42 | 30.1 (22.3–41.7) | 40 | 37.0 (26.5–50.4) | 22 | 26.8 (16.8–40.6) | .11 |
| Vaccine targeted (6, 11, 16, or 18) | 5 | 2.7 (.9–6.3) | 5 | 3.7 (1.2–8.6) | 18 | 16.7 (9.9–26.3) | 8 | 9.8 (4.2–19.2) | .001 |
| Any high risk | 30 | 16.2 (10.9–23.1) | 26 | 19.1 (12.5–28.0) | 28 | 25.9 (17.2–37.5) | 15 | 18.3 (10.2–30.2) | .30 |
| High risk, other than 16 and 18 | 28 | 15.1 (10.1–21.9) | 26 | 19.1 (12.5–28.0) | 22 | 20.4 (12.8–30.8) | 12 | 14.6 (7.6–25.6) | .77 |
| 6 or 11 | 2 | 1.1 (.1–3.9) | 2 | 1.5 (.2–5.3) | 10 | 9.3 (4.4–17.0) | 5 | 6.1 (2.0–14.2) | .003 |
| 16 or 18 | 3 | 1.6 (.3–4.7) | 3 | 2.2 (.5–6.4) | 10 | 9.3 (4.4–17.0) | 4 | 4.9 (1.3–12.5) | .02 |
| 31, 33, 45, 52, or 58 | 12 | 6.5 (3.4–11.3) | 16 | 11.8 (6.7–19.1) | 8 | 7.4 (3.2–14.6) | 3 | 3.7 (.8–10.7) | .50 |
Abbreviations: CI, confidence interval; HPV, human papillomavirus.
Table 2.
Prevalence of Penile HPV Genotypes by Age Group Among 511 Register-Confirmed Unvaccinated Australian Heterosexual Male Subjects
| HPV Genotype | Age 16–20 y (n = 185) | Age 21–25 y (n = 136) | Age 26–30 y (n = 108) | Age 31–35 y (n = 82) | Ptrend | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | ||
| Any | 39 | 21.1 (15.0–28.8) | 42 | 30.1 (22.3–41.7) | 40 | 37.0 (26.5–50.4) | 22 | 26.8 (16.8–40.6) | .11 |
| Vaccine targeted (6, 11, 16, or 18) | 5 | 2.7 (.9–6.3) | 5 | 3.7 (1.2–8.6) | 18 | 16.7 (9.9–26.3) | 8 | 9.8 (4.2–19.2) | .001 |
| Any high risk | 30 | 16.2 (10.9–23.1) | 26 | 19.1 (12.5–28.0) | 28 | 25.9 (17.2–37.5) | 15 | 18.3 (10.2–30.2) | .30 |
| High risk, other than 16 and 18 | 28 | 15.1 (10.1–21.9) | 26 | 19.1 (12.5–28.0) | 22 | 20.4 (12.8–30.8) | 12 | 14.6 (7.6–25.6) | .77 |
| 6 or 11 | 2 | 1.1 (.1–3.9) | 2 | 1.5 (.2–5.3) | 10 | 9.3 (4.4–17.0) | 5 | 6.1 (2.0–14.2) | .003 |
| 16 or 18 | 3 | 1.6 (.3–4.7) | 3 | 2.2 (.5–6.4) | 10 | 9.3 (4.4–17.0) | 4 | 4.9 (1.3–12.5) | .02 |
| 31, 33, 45, 52, or 58 | 12 | 6.5 (3.4–11.3) | 16 | 11.8 (6.7–19.1) | 8 | 7.4 (3.2–14.6) | 3 | 3.7 (.8–10.7) | .50 |
| HPV Genotype | Age 16–20 y (n = 185) | Age 21–25 y (n = 136) | Age 26–30 y (n = 108) | Age 31–35 y (n = 82) | Ptrend | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | ||
| Any | 39 | 21.1 (15.0–28.8) | 42 | 30.1 (22.3–41.7) | 40 | 37.0 (26.5–50.4) | 22 | 26.8 (16.8–40.6) | .11 |
| Vaccine targeted (6, 11, 16, or 18) | 5 | 2.7 (.9–6.3) | 5 | 3.7 (1.2–8.6) | 18 | 16.7 (9.9–26.3) | 8 | 9.8 (4.2–19.2) | .001 |
| Any high risk | 30 | 16.2 (10.9–23.1) | 26 | 19.1 (12.5–28.0) | 28 | 25.9 (17.2–37.5) | 15 | 18.3 (10.2–30.2) | .30 |
| High risk, other than 16 and 18 | 28 | 15.1 (10.1–21.9) | 26 | 19.1 (12.5–28.0) | 22 | 20.4 (12.8–30.8) | 12 | 14.6 (7.6–25.6) | .77 |
| 6 or 11 | 2 | 1.1 (.1–3.9) | 2 | 1.5 (.2–5.3) | 10 | 9.3 (4.4–17.0) | 5 | 6.1 (2.0–14.2) | .003 |
| 16 or 18 | 3 | 1.6 (.3–4.7) | 3 | 2.2 (.5–6.4) | 10 | 9.3 (4.4–17.0) | 4 | 4.9 (1.3–12.5) | .02 |
| 31, 33, 45, 52, or 58 | 12 | 6.5 (3.4–11.3) | 16 | 11.8 (6.7–19.1) | 8 | 7.4 (3.2–14.6) | 3 | 3.7 (.8–10.7) | .50 |
Abbreviations: CI, confidence interval; HPV, human papillomavirus.
Figure 1.
Prevalence of penile human papillomavirus (HPV) genotypes by age group among 511 register-confirmed unvaccinated Australian heterosexual male subjects.
